Outcomes and complications of hemodialysis in patients with renal cancer following bilateral nephrectomy
Author:
Shen Bing12, Luo Feng2, Yuan Nan2, Yin Jiaming2, Chai Yalin2, Sun Lijie2, Zhang Lin2, Luo Congjuan3
Affiliation:
1. Qingdao University , Qingdao 266071 , P.R. China 2. The Affiliated Hospital of Qingdao University , Qingdao 266000, Shandong , P.R. China 3. The Affiliated Hospital of Qingdao University , No. 16, Jiangsu Road, Shinan District , Qingdao 266000, Shandong , P.R. China
Abstract
Abstract
Objectives
The management of patients undergoing bilateral nephrectomy for renal cancer presents significant challenges, particularly in addressing hypotension, anemia, and tumor recurrence during hemodialysis.
Case presentation
A patient diagnosed with renal clear cell carcinoma in 2009 was followed until his demise in June 2022, with detailed documentation of symptoms, signs, laboratory results, diagnosis, and treatment. In the presented case, post-nephrectomy, the patient experienced frequent hypotension and anemia during dialysis, improving with erythropoietin-stimulating agents and subsequently with rosuvastatin. Later, multiple metastases were detected, correlating with normalized blood pressure and hemoglobin.
Literature review
A literature search up to September 2023 was also conducted, gathering data on hypotension, anemia, and tumor recurrence post-nephrectomy. Literature analysis of six cases revealed a 100% tumor recurrence rate in elderly patients (>50 years).
Conclusion
Treatment of anemia in bilateral nephrectomy patients warrants consideration of medication-induced tumor recurrence, highlighting early kidney transplantation to avoid adverse reactions like hypotension.
Publisher
Walter de Gruyter GmbH
Reference64 articles.
1. Bukavina L, Bensalah K, Bray F, Carlo M, Challacombe B, Karam JA, et al. Epidemiology of renal cell carcinoma: 2022 update. Eur Urol. 2022;82(5):529–42. 10.1016/j.eururo.2022.08.019. 2. Lobo J, Ohashi R, Amin MB, Berney DM, Compérat EM, Cree IA, et al. WHO 2022 landscape of papillary and chromophobe renal cell carcinoma. Histopathology. 2022;81(4):426–38. 10.1111/his.14700. 3. Li Z, Xu H, Yu L, Wang J, Meng Q, Mei H, et al. Patient-derived renal cell carcinoma organoids for personalized cancer therapy. Clin Transl Med. 2022;12(7):e970. 10.1002/ctm2.970. 4. Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial [published correction appears in Lancet Oncol. 2023 Jan;24(1):e10. 10.1016/S1470-2045(22)00759-8]. Lancet Oncol. 2022;23(9):1133–44. 10.1016/S1470-2045(22)00487-9. 5. Motzer RJ, Russo P, Haas N, Doehn C, Donskov F, Gross-Goupil M, et al. Adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma: final overall survival analysis of the phase 3 PROTECT trial. Eur Urol. 2021;79(3):334–8. 10.1016/j.eururo.2020.12.029.
|
|